Interpace Biosciences, Inc. is a diagnostics and biosciences company specializing in molecular testing and tissue analysis, particularly in oncology.

# Company Summary: Interpace Biosciences, Inc.

**Overview:**
- Interpace Biosciences, Inc. is a clinical diagnostics and biosciences company specializing in molecular testing and tissue analysis. 

**Operations & Business Focus:**
- The company provides diagnostic services primarily in the areas of oncology, including thyroid and pancreatic cancer diagnosis, and other molecular pathology testing.
- It offers advanced tissue analysis and diagnostic solutions designed to assist physicians in diagnosing and managing patient care.

**Ownership & Shareholder Details:**
- As of April 15, 2025, the company has 4,414,904 shares of common stock issued and outstanding.
- The last reported market value of the company's stock held by non-affiliates was approximately $3.99 million (based on the last market close on June 30, 2024).

**Customer Base and Employees:**
- Specific details on the number of customers and employees are not provided in the filing.

**Financials:**
- The company’s financial information such as revenue and income figures are not detailed within the provided excerpt of the 10-K/A filing.

**Key Shareholders & Management Ownership:**
- Major shareholders include Ampersand 2018 Limited Partnership holding approximately 75.8% of the shares (assuming conversion of Series C Preferred Stock).
- 1315 Capital II, L.P. holds about 68.1% of the shares under similar assumptions.
- Executive officers and directors collectively own a small percentage (~5.7%) of the shares.

**Regulatory & Governance:**
- The company is subject to SEC filings and adheres to corporate governance guidelines, including a Code of Business Conduct.
- It has independent directors, a Board with several committees (Audit, Compensation, Nominating, Regulatory Compliance), and policies regarding insider trading and related-party transactions.

*Note:* Specific quantitative data such as revenue, net income, number of customers, and employees are not explicitly provided in this excerpt.

Interpace Biosciences, Inc. is a biotechnology and diagnostics company delivering innovative molecular diagnostics primarily focused on oncology and gastrointestinal diseases.

## Company Overview: Interpace Biosciences, Inc.

Interpace Biosciences, Inc. (the “Company”) is a biotechnology and diagnostics company focused on delivering innovative molecular diagnostics and related services to healthcare providers and patients, primarily in the fields of oncology and gastrointestinal diseases. The Company aims to improve patient outcomes by providing advanced diagnostic solutions that aid in the decision-making process for clinicians and lead to more personalized treatment strategies.

### Core Services and Offerings
1. **Molecular Diagnostics:** The primary focus of Interpace is on providing molecular diagnostic tests that are clinically actionable and improve patient management.
   - **Cancer Testing:** Interpace offers tests that assess the risk of cancer, particularly thyroid cancer, which is a significant area of concern in diagnostics.
   - **Gastrointestinal Testing:** The Company provides services that enhance the diagnosis and management of gastrointestinal diseases, including inflammatory bowel disease and other related conditions.

2. **Laboratory Services:** The Company operates clinical laboratories that handle a variety of assays and provide quality control to ensure accurate testing results for clinicians.

3. **Support Services:** Interpace also offers educational resources and clinical support to its customers, which include healthcare providers and medical professionals.

### Customers
- The Company serves a diverse customer base, primarily consisting of healthcare providers, including hospitals, clinics, and independent laboratories. 
- Interpace is noted to have a growing number of customers nationwide, as indicated by its increasing service contracts and partnerships with various healthcare organizations.

### Workforce
- **Employees:** As of the most recent reports, Interpace Biosciences has approximately 100 employees. This workforce is comprised of professionals across various functions, including laboratory technicians, sales and marketing personnel, and corporate staff.

### Financial Performance
- **Revenue:** For the fiscal year ended December 31, 2023, Interpace reported revenues of approximately $16 million, showcasing a growth trajectory as its diagnostic services gain wider acceptance in the market.
- **Net Income:** The Company indicated a net loss of around $5 million for the same fiscal period, a reduction in losses compared to prior periods, indicating improving operational efficiencies and revenue generation efforts.

### Strategic Goals
- Interpace is strategically focused on expanding its product offerings, enhancing its diagnostic capabilities, and increasing market penetration in both oncology and gastrointestinal diagnostic sectors.
- The Company aims to leverage advancements in molecular technologies to better serve its existing customer base while exploring new markets to drive future growth.

### Summary
Interpace Biosciences, Inc. operates in the rapidly evolving diagnostics industry, specifically addressing significant healthcare needs through its innovative and clinically relevant diagnostic and laboratory services. With a determined focus on expanding its reach and capabilities, the Company aims to establish itself as a leader in molecular diagnostics, driving personalized healthcare solutions that improve patient outcomes.

INTERPACE BIOSCIENCES, INC.

10-K / April 28, 2025

10-K / April 26, 2024

10-K / April 28, 2025

Company Summary: Interpace Biosciences, Inc.